BioInvent International AB at Biostock Life Science Fall Summit Transcript
Happy to be here. And we'll try to give you a very condensed story of BioInvent, where we are at the moment, and the current status. Obviously, we are listed in Stockholm, as everybody know. So this is our forward-looking statement.
And then I would like to start with a quick snapshot of the company. So what we're doing at BioInvent, and obviously BioInvent is an expert in antibody discovery and development. But we have refocused a little bit in that sense that we are currently leveraging, as it says on this slide here, cancer biology, knowledge, immunology, and then antibody expertise.
And we're a little bit different to a lot of companies, so we are really pushing out with a broad portfolio. As you can see, we have currently five clinical projects running. And by next year, actually, we'll start our program number six. And this is possible since we are quite integrated company. So we do discovery of targets and antibodies based on a functional screening approach, which I will explain to you quickly on the next slide. We have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |